IGC Pharma
About: IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Employees: 61
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
30% more funds holding
Funds holding: 23 [Q3] → 30 (+7) [Q4]
0.05% more ownership
Funds ownership: 4.2% [Q3] → 4.25% (+0.05%) [Q4]
20% less capital invested
Capital invested by funds: $1.19M [Q3] → $954K (-$240K) [Q4]
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3.50
945%
upside
Avg. target
$3.88
1,057%
upside
High target
$4.25
1,169%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Alliance Global Partners James Molloy 36% 1-year accuracy 4 / 11 met price target | 945%upside $3.50 | Buy Reiterated | 6 Mar 2025 |
Ascendiant Capital Edward Woo 30% 1-year accuracy 21 / 70 met price target | 1,169%upside $4.25 | Buy Maintained | 24 Feb 2025 |
Financial journalist opinion
Based on 6 articles about IGC published over the past 30 days
Neutral
Accesswire
2 days ago
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.
POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.
Neutral
Accesswire
4 days ago
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"
POTOMAC, MD / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update research report entitled "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results" All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts.
Neutral
Accesswire
1 week ago
IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease, and frontotemporal degeneration, accurate diagnosis is critical to ensuring the right treatment strategy.
Neutral
Accesswire
3 weeks ago
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is expanding its Holiby™ wellness brand with the launch of two new product lines-Longevity and Renew-specifically designed to meet the increasing demand for anti-aging and cellular health solutions. Holiby is scaling its commercial strategy through direct-to-consumer e-commerce, white-label and private-label partnerships, and targeted influencer marketing and digital advertising.
Neutral
Accesswire
3 weeks ago
IGC Pharma Reports Third Quarter Fiscal 2025 Results
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended December 31, 2024. "The third quarter of fiscal 2025 was marked by our progress in advancing IGC-AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer's," said Mr.
Negative
Zacks Investment Research
4 weeks ago
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
Neutral
Accesswire
1 month ago
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
- Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the launch of Holiby™, a wellness brand offering scientifically formulated products for immune defense and sustained energy. This strategic expansion into the rapidly growing $75 billion wellness industry establishes a new revenue stream while IGC Pharma continues advancing its pharmaceutical pipeline focused on treatments for Alzheimer's disease and metabolic disorders.
Positive
Zacks Investment Research
1 month ago
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock?
IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Neutral
Accesswire
1 month ago
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC's innovative application of artificial intelligence (AI) and machine learning to advance early detection of Alzheimer's disease (AD) and improve patient outcomes.
Neutral
Accesswire
1 month ago
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital Markets on Thursday, January 23, 2025, at 1:00 pm ET. During the session, IGC Pharma's management will provide insights into the Company's recent progress, including advancements in its Alzheimer's pipeline, strategic expansion into metabolic disorders, and the integration of artificial intelligence in drug discovery.
Charts implemented using Lightweight Charts™